A second phase 3 trial of Viridian Therapeutics’ anti-IGF-1R antibody has hit its primary endpoint as the company prepares to file for FDA approval next year and challenge Amgen for a blockbuster market.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
